BridgeBio Pharma (BBIO) Stock Forecast & Price Target

$23.00 -0.72 (-3.04%)

(As of 01:08 PM ET)

BridgeBio Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
2

Buy
13

Based on 15 Wall Street analysts who have issued ratings for BridgeBio Pharma in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 2 have given a hold rating, and 13 have given a buy rating for BBIO.

Consensus Price Target

$47.57
106.83% Upside

According to the 15 analysts' twelve-month price targets for BridgeBio Pharma, the average price target is $47.57. The highest price target for BBIO is $70.00, while the lowest price target for BBIO is $37.00. The average price target represents a forecasted upside of 106.83% from the current price of $23.00.

Get the Latest News and Ratings for BBIO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BridgeBio Pharma and its competitors.

BBIO Analyst Ratings Over Time

Type	Current Forecast 11/19/23 to 11/18/24	1 Month Ago 10/20/23 to 10/19/24	3 Months Ago 8/21/23 to 8/20/24	1 Year Ago 11/19/22 to 11/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$47.57	$47.50	$48.09	$38.75
Forecasted Upside	106.83% Upside	82.55% Upside	87.42% Upside	32.48% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

I was wrong. Dead wrong. (Ad)

One small investment into these three companies at IPO and you’ve outperformed almost any other investment you could make. Unfortunately, you can’t go back in time and invest in what became the three most dominant companies in the tech world.

Click here to watch.

BBIO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BBIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BridgeBio Pharma Stock vs. The Competition

Type	BridgeBio Pharma	Medical Companies	S&P 500
Consensus Rating Score	2.87	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	99.29% Upside	28,619.81% Upside	9.78% Upside
News Sentiment Rating	Neutral News See Recent BBIO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Scotiabank 5 of 5 stars	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$44.00 ➝ $45.00	+93.97%
10/25/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$43.00 ➝ $43.00	+77.91%
10/17/2024	Leerink Partners 1 of 5 stars		Lower Target	Outperform ➝ Outperform	$47.00 ➝ $46.00	+76.86%
10/3/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$70.00 ➝ $70.00	+167.18%
9/11/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00	+40.05%
Get the Latest News and Ratings for BBIO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.
9/4/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$46.00	+60.06%
8/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$46.00 ➝ $43.00	+77.32%
8/7/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$50.00 ➝ $45.00	+80.65%
5/28/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$51.00 ➝ $47.00	+68.22%
3/21/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$45.00	+57.18%
3/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$60.00 ➝ $53.00	+63.81%
2/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$42.00 ➝ $46.00	+34.58%
1/31/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$37.00	+2.52%
12/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$58.00	+72.57%
7/18/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$29.00 ➝ $50.00	+56.05%
7/18/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.00 ➝ $42.00	+31.09%
7/17/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$24.00 ➝ $33.00	+3.00%
4/13/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$25.00 ➝ $27.00	+77.87%
2/6/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:28 PM ET.

BBIO Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for BridgeBio Pharma is $47.57, with a high forecast of $70.00 and a low forecast of $37.00.
: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BBIO shares.
: According to analysts, BridgeBio Pharma's stock has a predicted upside of 106.83% based on their 12-month stock forecasts.
: BridgeBio Pharma has been rated by research analysts at Bank of America, Cantor Fitzgerald, HC Wainwright, Leerink Partners, Oppenheimer, Piper Sandler, and Scotiabank in the past 90 days.
: Analysts like BridgeBio Pharma more than other "medical" companies. The consensus rating score for BridgeBio Pharma is 2.87 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BBIO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

🗓️ My First LIVE Event in 5 Years! (Ad)

Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.

Just click here and secure your spot!

This page (NASDAQ:BBIO) was last updated on 11/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Stock Forecast & Price Target